12 July 2023 - Duchesnay is pleased to announce that Slynd (drospirenone 4 mg), used to prevent pregnancy in girls and adult women aged 12 years and older who can become pregnant, is now listed for public reimbursement on the Public Prescription Drug Insurance Plan of the Régie de l'assurance maladie du Québec.

Slynd was approved on 17 May 2022, by Health Canada as a contraceptive that contains as a sole active ingredient, drospirenone 4 mg, a synthetic form of progesterone that has a similar pharmacological profile to the natural hormone progesterone.

Read Duchesnay press release